MedPath
FDA Approval

Agrylin

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
December 29, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Anagrelide(0.5 mg in 1 1)

Manufacturing Establishments4

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Patheon Manufacturing Services LLC

Takeda Pharmaceuticals America, Inc.

079415560

Powdersize, LLC

Takeda Pharmaceuticals America, Inc.

080120056

Catalent Pharma Solutions, LLC

Takeda Pharmaceuticals America, Inc.

119332987

Sterling Wisconsin, LLC

Takeda Pharmaceuticals America, Inc.

054452136

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Agrylin

Product Details

NDC Product Code
54092-063
Application Number
NDA020333
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
October 21, 2021
Code: VNS4435G39Class: ACTIMQuantity: 0.5 mg in 1 1
ANHYDROUS LACTOSEInactive
Code: 3SY5LH9PMKClass: IACT
CROSPOVIDONEInactive
Code: 2S7830E561Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
POVIDONE K30Inactive
Code: U725QWY32XClass: IACT
© Copyright 2025. All Rights Reserved by MedPath